跳至主要内容
临床试验/CTRI/2025/09/094082
CTRI/2025/09/094082尚未招募不适用

To Evaluate The Efficacy Of Drakshadi Churna In Childhood Tamaka Shwasa

Rishikul Campus1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年10月6日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
Clinical Evaluation of Drakshadi Churna in the management of Childhood Tamaka Shwasa

研究概览

简要总结

Tamaka Shwasa is a ‘Swatantra Vyadhi’ i.e., an independent disease entity having its etiology, pathophysiology, and management.Aacharya Charaka identifies both Vata and Kapha Doshas as key factors to the pathophysiology of Tamaka Shwasa. However, Sushruta Samhita, Madhav Nidana, and Yogratanakara specify Tamaka Shwasa as the Kapha Pradhan Vyadhi. In the present era, the escalating prevalence of recurrent airway disorders is observed in the global population.

The drug for this trial is Drakshadi Churna and the study aims to evaluate the efficacy of Drakshadi Churna in mild and intermittent cases of Tamaka shwasa.

The total duration of treatment is 35 days with assessment will be done at interval of 7 days. Patient will be registered OPD and IPD of P.G  department of Kaumarbhritya , Rishikul Campus ,UAU,Haridwar.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
5.00 Year(s) 至 11.00 Year(s)(—)
性别
All

入选标准

  • 1.Intermittent to mild cases of Asthma according to Global Initiative for Asthma (GINA) guidelines
  • 2.Children having classical features of Tamaka Shwasa.

排除标准

  • 1.Age group below 5 years and above 11 years.
  • 2.Severe asthma according to Global Initiative for Asthma (GINA) guidelines
  • 3.Patients with known cases of HIV, TB, Hep-B & Frequent H/O hospitalization due to status asthmatics.

结局指标

主要结局

Clinical Evaluation of Drakshadi Churna in the management of Childhood Tamaka Shwasa

时间窗: 7 days

Subjectively all signs & symptoms are given with grading depending upon their severity.

时间窗: 7 days

次要结局

  • Clinical Evaluation of Drakshadi Churna in the management of Childhood Tamaka Shwasa(Subjectively all signs & symptoms are given with grading depending upon their severity.)

研究者

发起方
Rishikul Campus
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr Reena Dixit

Rishikul Campus , Haridwar

研究点 (1)

Loading locations...

相似试验